Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Corey N. Fishman - President, CEO & Director Judith M.
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Matthews - Chief Financial Officer Conference Call Participants Matthew Keller - H.C. Wainwright Operator Hello, everyone, and thank you for joining the Iterum Therapeutics plc First Quarter 2025 Earnings and Business Update Call.
Iterum Therapeutics plc (NASDAQ:ITRM ) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Conference Call Participants Thomas Yip - H.C. Wainwright Operator Hello, everyone.
Iterum Therapeutics plc (NASDAQ:ITRM ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Executive Officer Judith Matthews - Chief Financial Officer Conference Call Participants Thomas Yip - HC Wainwright Jason Mccarthy - Maxim Group Operator Hello, everyone, and thank you for holding, and welcome to the Iterum Therapeutics Reports Third Quarter 2024 Financial Results. My name is Ezra [ph], and I will be your coordinator today.
Iterum Therapeutics plc (NASDAQ:ITRM ) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Director & CEO Steven Aronin - SVP & Head, Clinical Development Conference Call Participants Operator Hello, everyone, and welcome to Iterum Therapeutics call to discuss the recent approval of ORLYNVAH the treatment of Uncomplicated UTIs. My name is Lydia, and I'll be your operator today.
Iterum provides updates from the FDA's Antimicrobial Drugs Advisory Committee meeting on its NDA for oral sulopenem to treat adult women with uUTI.
Iterum Therapeutics plc (NASDAQ:ITRM ) Q2 2024 Results Conference Call August 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs & Secretary Corey Fishman - President, CEO & Director Judith Matthews - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group Operator Good morning, everyone. Welcome to Iterum Therapeutics Second Quarter 2024 Financial Results and Business Update.